Evidence map›Paper›PMID 40699687›Full record

ArticleCurrent issues in molecular biology2025

In Silico Identification of Potential Antagonists Targeting the HPV16 E2-E1 Interaction: A Step Toward Novel Therapeutics for Cervical Cancer.

Jesús Alonso Gandara-Mireles, Verónica Loera Castañeda, Julio Cesar Grijalva Ávila, Ignacio Villanueva Fierro, Cynthia Mora Muñoz, Hugo Payan Gándara, Guadalupe Antonio Loera Castañeda, Leslie Patrón Romero, Horacio Almanza Reyes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jesús Alonso Gandara-MirelesCIIDIR-Durango Unit, National Polytechnic Institute, Genomics Academy, Durango 34220, DG, Mexico.ORCID 0000-0002-5927-4992
Verónica Loera CastañedaCIIDIR-Durango Unit, National Polytechnic Institute, Genomics Academy, Durango 34220, DG, Mexico.
Julio Cesar Grijalva ÁvilaCIIDIR-Durango Unit, National Polytechnic Institute, Genomics Academy, Durango 34220, DG, Mexico.
Ignacio Villanueva FierroCIIDIR-Durango Unit, National Polytechnic Institute, Genomics Academy, Durango 34220, DG, Mexico.
Cynthia Mora MuñozEpidemiology Service, State Center of Cancerology, CECAN Durango, Durango 34000, DG, Mexico.
Hugo Payan GándaraEpidemiology Service, State Center of Cancerology, CECAN Durango, Durango 34000, DG, Mexico.
Guadalupe Antonio Loera CastañedaPrecipharm, Personalized and Precision Medicine Laboratory, Durango 64753, DG, Mexico.
Leslie Patrón RomeroFaculty of Medicine and Psychology, Autonomous University of Baja California, Tijuana 22390, BC, Mexico.ORCID 0000-0001-8981-055X
Horacio Almanza ReyesFaculty of Medicine and Psychology, Autonomous University of Baja California, Tijuana 22390, BC, Mexico.

Funding

Universidad Juárez del Estado de Durango, Mexico 23431
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antagonist moleculesantiviralcervical cancerhuman papillomavirus

Identifiers

PMID40699687
PMCPMC12025663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.